{"id":"W2235405584","doi":"10.1056/nejmoa1506859","title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2187,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Stand Up To Cancer; Genentech; European Society for Medical Oncology; Cilag; Astellas Pharma; National Institute for Health and Care Research; Sanofi; Public Health Agency; Prostate Cancer UK; GlaxoSmithKline; Les Laboratories Pierre Fabre; Medical Research Council; Celgene; Bristol-Myers Squibb; Prostate Cancer Foundation; American Association for Cancer Research; AstraZeneca; Royal Marsden NHS Foundation Trust; Pfizer; Oncolytics Biotech; Cancer Research UK","keywords":"Olaparib; Poly ADP ribose polymerase; Prostate cancer; DNA repair; Polymerase; Cancer research; PARP inhibitor; Medicine; Internal medicine; Oncology; Prostate; DNA; Cancer; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}